Lead Product(s): Polysulfated glycosaminoglycan
Therapeutic Area: Musculoskeletal
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: American Regent
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition April 01, 2020
The facility, previously owned by Daiichi Sankyo Europe, an affiliate of American Regent, produces the API for Adequan®i.m. and Adequan® Canine.